Home > Legal Library > Abstract

Supreme Court Decision Compels Brand-Name and Generic Drug Manufacturers Alike to Rethink Hatch-Waxman Litigation Strategies

by Cadwalader Wickersham Taft LLP - New York Office

June 21, 2013

Previously published on June 18, 2013

On June 17, 2013, in a decision long-awaited by antitrust and intellectual property practitioners, the U.S. Supreme Court ruled that so-called pharmaceutical "reverse payment" agreements are not immune from antitrust scrutiny but must be analyzed under the rule of reason.


The views expressed in this document are solely the views of the author and not Martindale-Hubbell. This document is intended for informational purposes only and is not legal advice or a substitute for consultation with a licensed legal professional in a particular case or circumstance.

View More Library Documents By...

Cadwalader Wickersham Taft LLP Overview